Parathyroid cancer screening

Jump to navigation Jump to search

Parathyroid cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Parathyroid cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Parathyroid cancer screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Parathyroid cancer screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Parathyroid cancer screening

CDC on Parathyroid cancer screening

Parathyroid cancer screening in the news

Blogs on Parathyroid cancer screening

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Parathyroid cancer screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

  • Germline DNA analysis for HRPT2/CDC73 is recommended among patients with parathyroid cancer, as early detection can benefit relatives and offsprings.

Screening

  • Germline DNA analysis for HRPT2/CDC73 is recommended among patients with parathyroid cancer, as early detection can benefit relatives and offsprings.

References


Template:WikiDoc Sources